(Q42203691)

18 October 2017

title

Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics (English)

1 reference

18 October 2017

main subject

anti-retroviral agent

0 references

1

Michael J Peluso

1 reference

18 October 2017

Serena Spudich

2

1 reference

18 October 2017

publication date

1 September 2014

1 reference

18 October 2017

published in

Current HIV/AIDS reports

1 reference

18 October 2017

volume

11

1 reference

18 October 2017

issue

3

1 reference

18 October 2017

page(s)

353-362

1 reference

https://scigraph.springernature.com/pub.10.1007/s11904-014-0223-y

18 October 2017

exact match

0 references

cites work

Central nervous system viral invasion and inflammation during acute HIV infection

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Updated research nosology for HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

The impact of HIV-associated neuropsychological impairment on everyday functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Prospective memory deficits are associated with unemployment in persons living with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Aging, prospective memory, and health-related quality of life in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Planning deficits in HIV-associated neurocognitive disorders: component processes, cognitive correlates, and implications for everyday functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Clinical correlates of HIV-associated neurocognitive disorders in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Raltegravir resistance in the cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Neurocognitive functioning in acute or early HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Psychiatric context of acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Longitudinal characterization of depression and mood states beginning in primary HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Genetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Alterations in brain metabolism during the first year of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Accelerated aging of selective brain structures in human immunodeficiency virus infection: a controlled, longitudinal magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Antiretroviral neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Central nervous system HIV infection in "less-drug regimen" antiretroviral therapy simplification strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

HIV protease inhibitor exposure predicts cerebral small vessel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Poor Aerobic Fitness May Contribute to Cognitive Decline in HIV-infected Older Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Physical exercise is associated with less neurocognitive impairment among HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0223-Y

Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex

21 January 2018

1 reference

12 December 2020

Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment

1 reference

12 December 2020

Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats

1 reference

12 December 2020

Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy

1 reference

12 December 2020

HIV-associated cognitive impairment before and after the advent of combination therapy

1 reference

12 December 2020

Memantine for AIDS dementia complex: open-label report of ACTG 301.

1 reference

12 December 2020

Adjunctive therapies for AIDS dementia complex

1 reference

12 December 2020

Brain Uptake of a Zidovudine Prodrug after Nasal Administration of Solid Lipid Microparticles

1 reference

12 December 2020

10.1007/S11904-014-0223-Y

Identifiers

DOI

1 reference

18 October 2017

1 reference